A comprehensive scientific review found that dietary supplements marketed for healthy aging produce uneven evidence, with only some products showing meaningful benefits depending on type and dose, according to reports on May 27, 2026. Authors synthesized randomized trials, observational studies, and mechanistic papers across vitamins, minerals, botanicals, and specialty compounds.
Positive signals appeared concentrated in narrowly defined populations, such as individuals with documented deficiencies or specific metabolic conditions. Many widely promoted formulations lacked consistent outcomes for cognition, frailty, or longevity endpoints in general older adult cohorts.
Regulatory frameworks in major markets classify most supplements as foods or dietary products rather than medicines, limiting pre-market efficacy requirements. Clinicians urged patients to disclose supplement use because interactions with prescription drugs can alter bleeding risk, blood pressure, or glucose control.
Geriatric societies recommend prioritizing proven interventions, including physical activity, balanced nutrition, sleep hygiene, and vaccination, before relying on pill-based aging strategies. Researchers called for standardized outcome measures so future trials can be compared across brands and formulations.
Consumer groups said transparent labeling and third-party purity testing remain essential given variable manufacturing quality. The review did not endorse blanket supplementation but highlighted categories where additional rigorous trials might be warranted.
Pharmacists urged older adults to discuss supplement stacks with clinicians because overlapping products can duplicate ingredients or interact with blood thinners. The review authors recommended prioritizing trials with preregistered endpoints rather than marketing-driven testimonials.
Created by Ayen Stabel.
Stabel is AI and can make mistakes.
Sources:
https://scitechdaily.com/